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H&E = haematoxylin and eosin; IHC = immunohistochemistry; PCR = polymerase chain reaction.
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Introduction
The pathological methods used to assess axillary lymph
node disease are of paramount importance because lymph
node status is a powerful prognostic factor at the time of
diagnosis. It has been shown through numerous studies
that routine histological examination of dissected nodes
may be inadequate depending on the thoroughness of
examination [1,2]. Sapir and Amromin were, in 1948, the
first to demonstrate this. They showed that, in 30 patients
whose lymph nodes were reported as negative by standard
histopathological methods using haematoxylin and eosin
(H&E), re-examination of multiple sections revealed 10
patients (33%) had metastatic disease [1]. Pickren [2],
working on lymph node specimens from 199 patients, simi-
larly found that 22% of those free of disease on routine
histopathological examination had occult metastasis using
serial sectioning. The presence of such metastatic disease
by serial sectioning has been shown to confer a significant
adverse effect on recurrence and survival in some series.
The major disadvantages, however, are the cost and labour
implications in processing axillary lymph nodes through
serial sectioning to search for occult disease.
Sentinel lymph node biopsy has rapidly emerged as a real
surgical option in the management of primary breast
cancer. The sensitivity of this method in axillary staging of
breast cancer has been evaluated in numerous studies
[3–10], and has been shown to depend on the pathologi-
cal methods used to assess the sentinel lymph node. By
reducing the number of lymph nodes to be studied, sen-
tinel lymph node dissection makes more exhaustive
histopathological examination possible. The optimal extent
of the histopathological work-up is yet to be determined
but, nonetheless, offers the possibility of examining lymph
nodes in much greater detail without the drawbacks of
cost and labour restrictions.
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Abstract
In embracing a multidisciplinary approach to the management of patients with sentinel node biopsy
in breast cancer, the pathologist task is to screen sentinel nodes for possible metastasis. The
consequences of missing sentinel node micrometastasis can directly influence treatment strategies,
and this screening therefore has to be performed with more attention than usual. There is presently
great diversity in the histopathological work-up of sentinel nodes, with many centres employing
additional techniques such as immunohistochemistry, reverse transcription polymerase chain
reaction or flow cytometry in addition to routine haematoxylin and eosin staining. In this review, we
address the pathological validation and significance of micrometastasis in sentinel node biopsy in
primary breast cancer.
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Pathological validation
There is presently no consensus for the optimal handling
of sentinel nodes in the laboratory. Most centres have
developed their own ‘in-house’ protocols, which are invari-
ably tied in with the institution’s research ambitions. This
ad hoc approach unfortunately can influence interpretation
of results, as the amount of material being assessed
between centres would be non-uniform even if we were to
ignore methodological differences.
In a number of large studies, using different histopatho-
logic techniques, the sentinel lymph node false negative
rate (defined as how often the sentinel lymph node is neg-
ative for malignancy when cancer is present in the rest of
the axilla) has varied between 0 and 11%. For example,
Giuliano et al [3] reported a false negative rate of 11% in a
series of 174 patients. Their group obtained a frozen
section intraoperatively and recommended taking perma-
nent sections from at least two levels of the tissue block at
40 µm intervals for H&E staining and cytokeratin immuno-
histochemistry [4]. Krag et al [5] similarly reported a false
negative rate of 11% in 405 patients. Lymph nodes were
either bisected or sliced multiple times and one to three
H&E sections were taken from the surface of each tissue
block. Results of a more detailed examination of lymph
nodes in 329 of these patients were reported by Weaver
et al [6]. H&E stained deeper sections at 100 and 200 µm
into the blocks, as well as cytokeratin immunohistochemi-
cal stains at 100 µm, were made and examined for all
lymph nodes. The authors reported an overall decrease in
residual axillary lymph node metastases from 13.3 to
11.1% after using deeper sections and immunohisto-
chemical stains. None of the newly detected metastases
were larger than 1 mm, and more than 60% of them had a
diameter of less than 0.1 mm.
O’Hea et al [7], in a study of 55 patients at the Memorial
Sloan-Kettering Cancer Centre, found a false negative rate
of 13% using the routine pathological technique with a
single section taken through each node. They reported
using frozen section examination of the sentinel node for all
patients with T1b or larger invasive cancers [8]. If the frozen
section proved to be negative, the remainder of each sen-
tinel lymph node is fixed and three additional sections are
taken and stained by both H&E and immunohistochemistry.
Veronesi et al [9] reported a false negative rate of 4.7% in
a study of 163 patients and, in another study from the
same centre, Viale et al [10] reported a false negative rate
of 7% in 155 patients. All sentinel lymph nodes in the latter
study were bisected and frozen. Fifteen pairs of adjacent
frozen sections were cut at 50 µm intervals (a total of 60
sections per lymph node). Additional pairs of sections were
cut at 100 µm intervals whenever residual tissue was left.
One section of each pair was stained with H&E and the
other for cytokeratins. Non-sentinel lymph nodes were
examined by standard histopathological techniques. Just
35.7% of positive nodes were detected on levels taken
beyond the second pair of sections, and so would be
missed if only one or two central sections were examined.
All metastatic foci were identified on H&E stained sections,
although in three cases cytokeratin immunoreactivity was
used to confirm the metastatic nature of cells. Viale et al
[10] concluded that the intraoperative examination of axil-
lary sentinel lymph nodes using serial sectioning is feasible
and effective in predicting the axillary lymph node status.
A number of studies have tried, however, to address the
question of optimal histopathologic examination of sentinel
lymph nodes by comparison of different protocols per-
formed on the same sample. Turner et al [4] examined 60
sentinel nodes, step sectioned at 10 levels separated by
40 µm, and stained by H&E and cytokeratin immunohisto-
chemistry (IHC). Nine sentinel nodes (15%) showed
metastases in the first two levels, but study of levels 3–10
revealed only two additional metastases (3%). In another
study, Cserni [11] reported the results of serial sectioning
and IHC staining of sentinel lymph nodes from 58
patients. Nodes were sectioned serially up to extinction of
the blocks and every 10th to 20th level was examined.
After every sixth section taken for H&E, one was taken for
IHC staining. The study showed that, in 8 out of 26 (31%)
positive nodes, the metastases could not be found if only
one or two central sections were examined. IHC staining
caused the detection of only two of these metastases.
While Zhang et al [12] reported that taking three levels at
approximately 25, 50 and 75% of the tissue blocks dis-
covered almost all metastases, the same strategy in the
study of Cserni [11] would have missed 15% of the
metastatic foci. van Diest [13] recommended, in an
accompanying editorial, four additional levels at 250 µm
intervals with H&E and IHC staining when the first-level
H&E section is negative.
A closer look at the literature interestingly reveals that the
Italian group of Veronesi et al [9] do not ‘lose’ tissue to the
molecular laboratory as do Guiliano et al [3]. The signifi-
cance of interpreting results from such heterogeneous
methodologies, where not all tissue is assessed
histopathologically, is clearly highlighted in a recent paper
by Dowlatshahi et al [14] who subjected the entire sen-
tinel lymph node from 52 patients to analysis and found
significant occult disease. Although the results of Dowlat-
shahi et al require prospective confirmation in larger
studies, it nonetheless emphasises the need for uniformity
in examining sentinel lymph nodes.
We at Nottingham City Hospital employ the MRC
ALMANAC protocol to assess all SNB. These nodes are
cut into slices about 3 mm thick, taken perpendicular to the
long axis to maximise the assessment of the marginal sinus,
with one node per cassette. We have found in our experi-
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ence that the majority of nodes can be completely embed-
ded in one cassette. Larger nodes have alternate slices
embedded and may require more than one cassette. Very
large obviously involved nodes have one section taken. This
approach is consistent with recommendations of the
National Health Service Breast Screening Programme [15].
Some authors have advocated intraoperative frozen sec-
tions or imprint cytology of axillary lymph nodes. Conven-
tional frozen sections, we believe, have an unacceptably
high false negative rate of 10–30% [16–19]. More inten-
sive intraoperative assessment with serial sections and
immunohistochemistry has been described, but this is time
consuming and labour intensive. A frozen section might be
appropriate in selected cases; for example, if the node is
macroscopically abnormal and this is confirmed histologi-
cally to be metastatic carcinoma, further axillary surgery
can be performed immediately. Some studies have found
low false negative rates of 2–3% with intraoperative
imprint cytology [16,20], but not all have been able to
achieve this level of accuracy [18]. Most breast carcino-
mas can be diagnosed preoperatively, and we extremely
rarely perform frozen section diagnosis of the primary
tumour. Our feeling is that frozen section and imprint cytol-
ogy assessment of axillary nodes is also inappropriate.
Reverse transcription polymerase chain reaction (PCR) is
even more sensitive than immunohistochemistry at detect-
ing metastatic tumour [21,22]. Two types of method can
be used to detect tumour cells with molecular techniques.
Firstly, a genetic defect such as chromosomal rearrange-
ment or mutation can be identified. The problem with this
method is that no genetic defect is seen in all breast carci-
nomas. The second method is based on a molecular
marker that is transcribed by tumour cells, but not by the
adjacent tissue. To obtain a marker that has this specificity
and is expressed in the majority of tumours is difficult. It
may be necessary to use a panel of markers. A major
problem with PCR is a high false positive rate due to the
sensitivity of the method. It is also not possible with PCR
to determine whether the DNA comes from a viable cell.
An advantage of H&E sections and IHC is that the mor-
phology of the cells can be examined and malignancy con-
firmed. A major unresolved question is whether carcinoma
detected only by PCR is of prognostic significance.
Clinical significance of micrometastasis
There is no universally agreed definition of micrometasta-
sis. Huvos et al defined micrometastasis as metastatic foci
less than 2 mm in diameter [23] and this is still widely
used. In fact, the fifth edition of the AJCC staging manual
uses the same definition; however, the arbitrary cutoff
point varies between 0.2 and 2 mm in various studies.
The detection rate of micrometastases in axillary lymph
nodes has been reported to range from 9 to 46% [14,24].
Studies have used serial sectioning with or without immuno-
histochemical stains for the detection of micrometastatic
foci and, as described, these methods have been shown to
have a definite impact on detection rates.
Despite all this, the clinical significance of micrometastasis
is yet to be determined. Nodal micrometastases appear to
have a small but significant adverse effect on distant recur-
rence and survival in some studies, but not in all [16]. It is
imperative that the prognostic significance of nodal
micrometastases be determined, as there are important
implications for systemic adjuvant chemotherapy and hor-
monal therapy. The International (Ludwig) Breast Cancer
Study [25], one of the largest micrometastases studies
performed to date, showed that both disease free interval
and overall survival were significantly affected by the pres-
ence of micrometastatic disease at 5 and 6 years of follow-
up. At 6 years median follow-up, DFS was reduced from
71% in the node negative group to 53% in micrometastatic
node positive patients (P = 0.0008). The overall survival
was 80% in the node negative group and 70% in the node
positive group (P = 0.0009) [26]. Rosen et al found that
patients had poorer disease free interval and overall sur-
vival at 10 years with nodal metastasis smaller than 2 mm.
However, this described a group with T1 tumours, whereas
no survival disadvantage as such was found in T2 cancer
[27]. Present-day data of sentinel lymph node micrometas-
tases do not possess sufficient follow-up to observe any
survival effects as some retrospective studies have shown,
and therefore the prognostic significance of such occult
metastasis at this time is unknown.
Conclusion
The traditional ‘Halsted’ view of breast cancer was that
there was a logical sequential pattern of spread of the car-
cinoma, and this was used to justify radical surgery. Fisher
et al [28] and other workers have more recently proposed
that carcinoma of the breast is often disseminated at the
time of diagnosis, and that nodal metastases are merely a
marker of systemic disease. There is a trend towards less
radical surgery to both the breast and the axilla associated
with this philosophical change. Axillary sentinel lymph node
biopsy is thus a reversion to the ‘Halsted’ philosophy, while
at the same time continuing the trend towards less radical
surgery. In reality, the truth probably lies somewhere
between the ‘Halsted’ and ‘Fisher’ models. Two central
questions particularly require answers from clinical trials:
whether patients with a negative sentinel axillary lymph
node(s) can safely avoid further axillary surgery, and the
clinical significance of micrometastases. Of critical impor-
tance to both these questions is the way in which the
pathologist should assess the node biopsy, and thus how
negative and positive nodes are defined. The cost in time,
equipment and consumables needs to be compared for
sentinel node biopsy and other forms of axillary surgery.
Comparison of the effectiveness of sentinel node biopsy
Available online http://breast-cancer-research.com/content/3/2/113
with axillary node sampling also needs to be addressed,
and this forms part of the UK ALMANAC study.
References
1. Sapir O, Amromin GD: Obscure axillary lymph node metastasis
in carcinoma of the breast. Cancer 1948; 1:238–241.
2. Pickren JW: Significance of occult metastasis: a study of
breast cancer. Cancer 1961; 14:1266–1271.
3. Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic
mapping and sentinel lymphadenectomy for breast cancer.
Ann Surg 1994; 220:391–398.
4. Turner RR, Ollila DW, Stern S, Giuliano AE: Optimal histopatho-
logic examination of the sentinel lymph node for breast carci-
noma staging. Am J Surg Pathol 1999; 23:263–267.
5. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C,
Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P:
The sentinel node in breast cancer — a multicenter validation
study. N Engl J Med 1998; 339:941–946.
6. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O’Connell M:
Pathologic analysis of sentinel and nonsentinel lymph nodes
in breast carcinoma: a multicenter study. Cancer 2000; 88:
1099–1107.
7. O’Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG,
Borgen PI, Cody HS III: Sentinel lymph node biopsy in breast
cancer: initial experience at Memorial Sloan-Kettering Cancer
Center. J Am Coll Surg 1998; 186:423–427.
8. Cody HS III, Borgen PI: State-of-the-art approaches to sentinel
node biopsy for breast cancer: study design, patient selection,
technique, and quality control at Memorial Sloan-Kettering
Cancer Center. Surg Oncol 1999; 8:85–91.
9. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni
M, Costa A, de Cicco C, Geraghty JG, Luini A, Sacchini V,
Veronesi P: Sentinel-node biopsy to avoid axillary dissection in
breast cancer with clinically negative lymph nodes. Lancet
1997; 349:1864–1867.
10. Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, Veronesi P,
Paganelli G, Bedoni M, Orvieto E: Intraoperative examination of
axillary sentinel lymph nodes in breast carcinoma patients.
Cancer 1999; 85:2433–2438.
11. Cserni G: Metastases in axillary sentinel lymph nodes in
breast cancer as detected by intensive histopathological work
up. J Clin Pathol 1999; 52:922–924.
12. Zhang PJ, Reisner RM, Nangia R, Edge SB, Brooks JJ: Effective-
ness of multiple-level sectioning in detecting axillary nodalmi-
crometastasis in breast cancer: a retrospective study with
immunohistochemical analysis. Arch Pathol Lab Med 1998;
122:687–690.
13. van Diest PJ: Histopathological workup of sentinel lymph
nodes: how much is enough? J Clin Pathol 1999; 52:871–873.
14. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC Jr:
Occult metastases in the sentinel lymph nodes of patients
with early stage breast carcinoma: a preliminary study. Cancer
1999; 86:990–996.
15. National Coordinating Group for Breast Screening Pathology:
Pathology Reporting in Breast Cancer Screening. Sheffield:
National Health Service Breast Screening Programme, 1995.
16. Fisher CJ, Boyle S, Burke M, Price AB: Intraoperative assess-
ment of nodal status in the selection of patients with breast
cancer for axillary clearance. Br J Surg 1993; 80:457–458.
17. Galimberti V, Zurrida S, Zucali P, Luini A: Can sentinel node
biopsy avoid axillary dissection in clinically node-negative
breast cancer patients? Breast 1998; 7:8–10.
18. van Diest PJ, Torrenga H, Borgstein PJ, Pijpers R, Bleichrodt RP,
Rahusen FD, Meijer S: Reliability of intraoperative frozen
section and imprint cytological investigation of sentinel lymph
nodes in breast cancer. Histopathology 1999; 35:14–18.
19. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S,
Robertson C, Sacchini V, Veronesi P, Orvieto E, De Cicco C, Intra
M, Tosi G, Scarpa D: Sentinel lymph node biopsy and axillary
dissection in breast cancer: results in a large series. J Natl
Cancer Inst 1999; 91:368–373.
20. Rubio IT, Korourian S, Cowan C, Krag DN, Colvert M, Klimberg
VS: Sentinel lymph node biopsy for staging breast cancer. Am
J Surg 1998; 176:532–535.
21. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S,
Koyama H: The detection of breast carcinoma micrometas-
tases in axillary lymph nodes by means of reverse transcrip-
tase-polymerase chain reaction. Cancer 1994; 74:1595–1160.
22. Schoenfeld A, Luqmani Y, Smith D, O’Reilly S, Shousha S,
Sinnett HD, Coombes RC: Detection of breast cancer
micrometastases in axillary lymph nodes by using poly-
merase chain reaction. Cancer Res 1994; 54:2986–2990.
23. Huvos AG, Hutter RV, Berg JW: Significance of axillary
macrometastases and micrometastases in mammary cancer.
Ann Surg 1971; 173:44–46.
24. Dowlatshahi K, Fan M, Snider HC, Habib FA: Lymph node
micrometastases from breast carcinoma: reviewing the
dilemma. Cancer 1997; 80:1188–1197.
25. International (Ludwig) Breast Cancer Study Group: Prognostic
importance of occult axillary lymph node micrometastases
from breast cancers. Lancet 1990; 335:1565–1568.
26. Neville AM, Price KN, Gelber RD, Goldhirsch A: Axillary node
micrometastases and breast cancer [letter]. Lancet 1991; 337:
1110.
27. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: A long
term follow up study of survival in stage I (T1N0M0) and stage
II (T1N0M0) breast carcinoma. J Clin Oncol 1989; 7:355–366.
28. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M: The
accuracy of clinical nodal staging and of limited axillary dis-
section as a determinant of histologic nodal status in carci-
noma of the breast. Surg Gynecol Obstet 1981; 152:765–772.
Breast Cancer Research    Vol 3 No 2 Rampaul et al
